Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
The Expanding Role of Antibody-Drug Conjugates in Breast Cancer Treatment: Oranus Mohammadi, MD
Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.
Real-World Perspectives on ctDNA Applications in Breast Cancer Management: Oranus Mohammadi, MD
Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.
Integrating ctDNA Into Breast Cancer Management: Joanne Mortimer, MD, FACP, FASCO
Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, challenges in patient communication and payer coverage, and unique barriers for male patients.
Addressing Learning Curves in Rare NSCLC Subtypes and Targeted Therapy Use: Jorge Nieva, MD
Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.
Overcoming Barriers to Molecular Testing in NSCLC Care: Jorge Nieva, MD
Jorge Nieva, MD, highlights the critical role of molecular testing in non–small cell lung cancer (NSCLC) care, while addressing barriers such as limited tissue samples, delayed turnaround times, and the need for faster, more accessible diagnostic technologies.
Improving Clinical Trial Diversity Through Language-Inclusive Approaches: Daniel Virnich, MD
Daniel Virnich, MD, highlights the need for proactive social determinants of health screening, language-inclusive clinical trial practices, value-based treatment decisions, and policy reforms to improve equitable access to cancer care.
Clinical Considerations for Immunotherapy Sequencing in NSCLC: Lauren Antrim, MD
Lauren Antrim, MD, of City of Hope Cancer Center Duarte, emphasized the need for more evidence to guide optimal immunotherapy duration and sequencing in in non–small cell lung cancer (NSCLC), highlighting ongoing trials and the potential role of ctDNA in tailoring treatment strategies.
Balancing Safety, Cost, and Duration in Immunotherapy for NSCLC: Lauren Antrim, MD
Lauren Antrim, MD, emphasized the need to balance safety, efficacy, and financial considerations when managing immune checkpoint inhibitors in NSCLC, underscoring the importance of patient-centered discussions and ongoing trials to refine treatment duration strategies.
Addressing Financial and Socioeconomic Barriers to Precision NSCLC Care: Jonathan Thompson, MD, MS
Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker testing and advanced therapies, underscoring the need for provider advocacy and systemic support.
Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.
Navigating Perioperative Immunotherapy Decisions in Lung Cancer Care: Jonathan Thompson, MD, MS
Jonathan Thompson, MD, MS, explains that adjuvant immunotherapy benefits patients with early-stage lung cancer with incomplete neoadjuvant response, while treatment decisions in the adjuvant setting must weigh efficacy, toxicity, and limited evidence.
Expanding the Role of NGS and Retesting in Early and Refractory NSCLC: Jonathan Thompson, MD, MS
Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective retesting at progression can identify resistance mutations or new targets to optimize value-based care.
Embedding Reflex Biomarker Testing to Advance Precision Lung Cancer Care: Jonathan Thompson, MD, MS
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision therapy in lung cancer and to address persistent disparities in timely, equitable access to care.